JP2020522474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522474A5 JP2020522474A5 JP2019565011A JP2019565011A JP2020522474A5 JP 2020522474 A5 JP2020522474 A5 JP 2020522474A5 JP 2019565011 A JP2019565011 A JP 2019565011A JP 2019565011 A JP2019565011 A JP 2019565011A JP 2020522474 A5 JP2020522474 A5 JP 2020522474A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022211728A JP2023030174A (ja) | 2017-05-23 | 2022-12-28 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510168P | 2017-05-23 | 2017-05-23 | |
| US201762510167P | 2017-05-23 | 2017-05-23 | |
| US201762510137P | 2017-05-23 | 2017-05-23 | |
| US201762510169P | 2017-05-23 | 2017-05-23 | |
| US62/510,167 | 2017-05-23 | ||
| US62/510,169 | 2017-05-23 | ||
| US62/510,137 | 2017-05-23 | ||
| US62/510,168 | 2017-05-23 | ||
| US201762539425P | 2017-07-31 | 2017-07-31 | |
| US62/539,425 | 2017-07-31 | ||
| PCT/US2018/034221 WO2018217945A1 (en) | 2017-05-23 | 2018-05-23 | A protein binding nkg2d, cd16 and a tumor-associated antigen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211728A Division JP2023030174A (ja) | 2017-05-23 | 2022-12-28 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522474A JP2020522474A (ja) | 2020-07-30 |
| JP2020522474A5 true JP2020522474A5 (enExample) | 2021-07-26 |
Family
ID=64395873
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565011A Pending JP2020522474A (ja) | 2017-05-23 | 2018-05-23 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
| JP2022211728A Pending JP2023030174A (ja) | 2017-05-23 | 2022-12-28 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211728A Pending JP2023030174A (ja) | 2017-05-23 | 2022-12-28 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200157226A1 (enExample) |
| EP (1) | EP3630181A4 (enExample) |
| JP (2) | JP2020522474A (enExample) |
| KR (1) | KR20200010429A (enExample) |
| CN (1) | CN111278460A (enExample) |
| AU (1) | AU2018273250A1 (enExample) |
| BR (1) | BR112019024620A2 (enExample) |
| CA (1) | CA3064567A1 (enExample) |
| IL (1) | IL270801A (enExample) |
| MX (1) | MX2019013995A (enExample) |
| WO (1) | WO2018217945A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EP3941523A4 (en) | 2019-03-22 | 2022-12-28 | Mayo Foundation for Medical Education and Research | MATERIALS AND METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE |
| CN115708411A (zh) * | 2020-04-16 | 2023-02-21 | 南通壹宸生物医药科技有限公司 | 一种pd-1突变体多肽及其制备和用途 |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| JP2024537779A (ja) * | 2021-09-29 | 2024-10-16 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｂａｆｆ－ｒに結合するタンパク質 |
| US20230203202A1 (en) * | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| AU2023314795A1 (en) | 2022-07-29 | 2025-03-06 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
| EP4619023A1 (en) | 2022-11-15 | 2025-09-24 | Calico Life Sciences LLC | Anti-papp-a antibodies and methods of use thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025166040A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| UY33707A (es) * | 2010-11-04 | 2012-05-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2012125850A1 (en) * | 2011-03-16 | 2012-09-20 | Amgen Inc. | Fc variants |
| BR112015006824A2 (pt) * | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| DE102013019352A1 (de) * | 2013-11-13 | 2015-09-17 | Elke Pogge Von Strandmann | Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort |
| EP4050026A1 (en) * | 2014-04-01 | 2022-08-31 | Adimab, LLC | Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody |
| US10647768B2 (en) * | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
| WO2016022939A1 (en) * | 2014-08-08 | 2016-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies specific for 5t4 and methods of their use |
| MX384198B (es) * | 2014-12-19 | 2025-03-14 | Chiome Bioscience Inc | Proteina de fusion que comprende tres dominios de union a 5t4 y cd3. |
| WO2016122701A1 (en) * | 2015-01-26 | 2016-08-04 | Macrogenics, Inc. | Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof |
| CN107530424A (zh) * | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | 针对nkg2d和肿瘤相关抗原的二价抗体 |
| JP6840682B2 (ja) * | 2015-06-23 | 2021-03-10 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的抗原結合タンパク質 |
| US20180327499A1 (en) * | 2015-11-13 | 2018-11-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| US20200048347A1 (en) * | 2016-09-01 | 2020-02-13 | Immunomab, Inc. | Bispecific antibodies |
| CN110944651A (zh) * | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
-
2018
- 2018-05-23 CA CA3064567A patent/CA3064567A1/en active Pending
- 2018-05-23 US US16/615,231 patent/US20200157226A1/en not_active Abandoned
- 2018-05-23 JP JP2019565011A patent/JP2020522474A/ja active Pending
- 2018-05-23 KR KR1020197037753A patent/KR20200010429A/ko not_active Ceased
- 2018-05-23 EP EP18805878.8A patent/EP3630181A4/en not_active Withdrawn
- 2018-05-23 AU AU2018273250A patent/AU2018273250A1/en not_active Abandoned
- 2018-05-23 WO PCT/US2018/034221 patent/WO2018217945A1/en not_active Ceased
- 2018-05-23 CN CN201880051761.6A patent/CN111278460A/zh active Pending
- 2018-05-23 MX MX2019013995A patent/MX2019013995A/es unknown
- 2018-05-23 BR BR112019024620-7A patent/BR112019024620A2/pt not_active Application Discontinuation
-
2019
- 2019-11-20 IL IL270801A patent/IL270801A/en unknown
-
2022
- 2022-12-28 JP JP2022211728A patent/JP2023030174A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521448A5 (enExample) | ||
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2021035388A5 (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| JP2020508997A5 (enExample) | ||
| JP2021098733A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2020522473A5 (enExample) | ||
| JP2021512630A5 (enExample) | ||
| JP2021534096A5 (enExample) | ||
| JP2022515318A5 (enExample) | ||
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| JP2021098732A5 (enExample) | ||
| JP2020103301A5 (enExample) | ||
| JP2021523140A5 (enExample) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2019536430A5 (enExample) | ||
| JP2023106433A5 (enExample) | ||
| RU2019128134A (ru) | Антитело против gprc5d и молекула, содержащая антитело | |
| JP2021522162A5 (enExample) | ||
| JP2021523913A5 (enExample) | ||
| JP2020510646A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2019501883A5 (enExample) | ||
| JP2020507577A5 (enExample) | ||
| RU2019129511A (ru) | Белки, связывающие gd2, nkg2d и cd16 |